Ketamine and SSRI Discontinuation: Never Stop Your Antidepressant to Start Ketamine

The myth: “I have to come off my antidepressant first”

The single most common pre-consultation question we hear at Music City Ketamine sounds something like this: “Do I need to be off my SSRI before my first infusion?” The short answer is almost always no. The longer answer matters, because acting on this myth can cause real harm.

Patients arrive with this idea from a few different places. Some have read forum posts suggesting antidepressants “cancel out” ketamine. Some have been told by a friend or even another provider that they need a clean medication slate to give the infusion a fair shot. Some are simply tired of being on an SSRI and view ketamine as an exit ramp. None of these reasons justify the risk of a self-directed taper.

Ketamine is FDA-approved as an anesthetic; its use for depression, anxiety, PTSD, and chronic pain is off-label. That regulatory framing matters here, because it means the most reliable evidence on how ketamine interacts with other psychiatric medications comes from researchers who have specifically studied the question rather than from drug labels. The evidence, as we will lay out below, generally supports keeping you on your current antidepressant while ketamine is added to the picture.

What Andrade 2017 actually said about interactions

The most-cited reference on this topic is a series of pharmacology reviews by Chittaranjan Andrade published in the Journal of Clinical Psychiatry in 2017 (the drug-interactions installment of the series, 78:e858–e861, and related parts). Andrade walked carefully through the pharmacokinetic and pharmacodynamic interactions between ketamine and the antidepressants patients are most likely to be taking.

The review came to a few practical conclusions. First, most conventional antidepressants—SSRIs, SNRIs, bupropion, mirtazapine, tricyclics—combine safely with ketamine in the doses used for treatment-resistant depression. Second, ketamine is metabolized primarily through the liver enzymes CYP2B6 and CYP3A4. Drugs that strongly induce or inhibit those enzymes can shift ketamine exposure up or down, but the SSRIs most commonly prescribed are not in that high-risk category. Third, benzodiazepines may blunt the antidepressant effect of ketamine through their action at the GABA system; this is a timing question to discuss with your prescribing clinician, not a reason to abruptly stop.

The take-home from Andrade’s work is that the interaction picture for ketamine plus an SSRI is reassuring. That matches what we see in clinic and what is reflected in our broader medication interactions overview. Patients on sertraline, escitalopram, fluoxetine, citalopram, and similar SSRIs routinely respond well to ketamine for treatment-resistant depression without any change to their existing prescription.

SSRI discontinuation syndrome — the real risk

The reason we are emphatic about not stopping an SSRI to prepare for ketamine is that SSRI discontinuation syndrome is a well-characterized clinical phenomenon. A systematic review by Fava and colleagues published in Psychotherapy and Psychosomatics in 2015 described its incidence, symptom profile, and the relationship between half-life and severity. The most common features include dizziness, paresthesias often described as “brain zaps,” gastrointestinal upset, flu-like symptoms, irritability, and rebound mood symptoms that can mimic a depressive relapse.

Symptoms typically begin within one to seven days of an abrupt dose reduction or stop. They can persist for weeks in some patients. They are not rare; depending on the agent, between 30% and 60% of patients who stop suddenly will experience at least some discontinuation symptoms. They are also not a sign of addiction—they reflect the nervous system’s adjustment to the absence of a drug it has adapted around.

The clinical risk for someone trying to “be ready” for ketamine is twofold. The discontinuation symptoms themselves are unpleasant and can be confused with a psychiatric crisis. And the rebound mood symptoms can muddy the assessment of whether ketamine is actually helping. If you arrive at your first infusion already destabilized by an unsupervised stop, neither you nor we can cleanly tell what ketamine is doing.

Half-life matters — paroxetine vs. fluoxetine vs. SNRIs

Discontinuation syndrome severity tracks tightly with the half-life of the medication. Short-half-life agents drop quickly out of the bloodstream and the brain after a missed dose; long-half-life agents taper themselves naturally as serum levels fall over days.

The worst offenders, by a wide margin, are paroxetine (Paxil, half-life around 21 hours) and venlafaxine (Effexor, half-life around 5 hours for the parent compound). Patients who miss even a single dose of these agents can feel discontinuation symptoms within a day. Sertraline (Zoloft) and citalopram/escitalopram (Celexa, Lexapro) sit in the middle. Fluoxetine (Prozac), with a parent half-life of one to three days and an active metabolite of seven to fifteen days, is famously gentle to come off because it tapers itself.

Horowitz and Taylor argued in Lancet Psychiatry in 2019 that hyperbolic tapering—reducing the dose by progressively smaller absolute amounts as the dose gets lower—produces fewer discontinuation symptoms than the linear schedules historically taught. Abrupt cessation, by contrast, drives the highest rate of withdrawal symptoms across every agent studied. Their work has reshaped how thoughtful prescribers approach SSRI discontinuation when it is clinically appropriate. None of this can or should be done unilaterally by the patient.

Benzodiazepines: the one nuance worth discussing

Where the conversation gets more textured is with benzodiazepines. Several research groups have observed that patients on standing benzodiazepine therapy—clonazepam, alprazolam, lorazepam—sometimes show a reduced antidepressant response to ketamine. The proposed mechanism is that benzodiazepines enhance GABAergic inhibition in a way that may dampen the glutamate surge ketamine produces.

The evidence is suggestive rather than conclusive. What we take from it clinically is that timing of benzodiazepine doses around an infusion is worth discussing, not that anyone should abruptly stop a benzodiazepine. Benzodiazepine withdrawal carries its own well-documented risks, including seizures, that are categorically more dangerous than SSRI discontinuation. If you are on a daily benzodiazepine, that conversation belongs to your prescribing clinician and to us together—never to a self-directed plan.

MAOIs are the one class that warrants extra caution. Interaction risk between MAOIs and ketamine is meaningfully higher than with SSRIs or SNRIs, and any decision about how to manage that medication around ketamine should be made by the psychiatrist who prescribed it. We coordinate with that clinician directly when this comes up.

What we actually ask you to keep, change, or pause around an infusion

Here is what an actual first infusion looks like in practice for someone on a standard SSRI. We ask you to take your antidepressant on the morning of your appointment as you normally would. We ask you to come in fasting per our pre-infusion instructions. We do not ask you to skip, hold, or taper your SSRI.

For benzodiazepines, we usually ask whether you can shift the timing of your dose so the infusion does not fall at peak benzodiazepine plasma level—a small adjustment, made in coordination with your prescriber, not a change in the underlying prescription. For stimulants like amphetamine or methylphenidate, we typically ask you to hold the morning dose because of the cardiovascular interaction with ketamine, and resume normally afterward.

We coordinate proactively with prescribers when there is anything more nuanced. Your PCP or prescribing psychiatrist should know you are starting ketamine, and we will share documentation directly with them at your request. The goal is not for ketamine to replace what is working in your current regimen. The goal is for ketamine to add a different mechanism—NMDA receptor modulation and rapid-onset glutamate effects—to whatever else is helping, so the overall plan moves you forward.

Talking to your prescriber, not us, about med changes

If your long-term goal includes reducing or stopping an antidepressant, that is a legitimate clinical conversation. It is also one that belongs squarely with the clinician who prescribed the medication. We are CRNA-led and infusion-focused; we are not the right team to manage an SSRI taper, and we will not pretend otherwise.

What we can do is communicate. If your prescribing clinician wants to know how you are responding to ketamine before considering any taper, we will provide that information. If they want to wait three months after a course of infusions to evaluate stability before changing the antidepressant, that is a reasonable and conservative plan. If they want to leave your SSRI exactly where it is indefinitely, that is also reasonable.

What we will not do is encourage you to stop, lower, or hold an antidepressant on your own. Studies indicate that abrupt cessation of SSRIs—especially short-half-life agents—produces the highest rate of discontinuation symptoms and rebound mood instability. Research suggests that the combination of an SSRI and ketamine is generally safe and clinically reasonable. The data, the safety logic, and the standard of care all point in the same direction: keep the medication that is working, add ketamine alongside it, and let your prescribing clinician own any future change.

Marla Peterson, CRNA, oversees every infusion at Music City Ketamine and reviews your full medication list before treatment begins. If anything in your regimen genuinely needs adjustment for safety reasons, we will tell you, and we will tell your prescriber. A lot of common ketamine myths evaporate once a real clinical conversation happens. The myth that you have to be off your SSRI to do this work is one of the easiest to dispel.

If you are weighing ketamine for depression and feeling pressure to make medication changes you did not plan, slow down. Schedule a consultation, bring your medication list, and let us walk through it with you. That is what the visit is for.